Publications by authors named "Laura L Carter"

Claim this Profile
P
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.
Soni Savai Pullamsetti, Ravikumar Sitapara, Robin Osterhout, Astrid Weiss, Laura L Carter

Int J Mol Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity.
Xiuting Liu, Graham D Hogg, Chong Zuo, Nicholas C Borcherding, John M Baer, Laura L Carter

Cancer Cell· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Anna Galkin, Ravikumar Sitapara, Bryan Clemons, Eduardo Garcia, Michael Kennedy, Laura L Carter

Eur Respir J· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer.
Thomas D Aicher, Chad A Van Huis, Alexander R Hurd, Donald J Skalitzky, Clarke B Taylor, Laura L Carter

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment.
Xikui Liu, Elizabeth M Zawidzka, Hongxiu Li, Charles A Lesch, Jenna Dunbar, Laura L Carter

Cancer Immunol Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness .
Xiao Hu, Kinga Majchrzak, Xikui Liu, Megan M Wyatt, Chauncey J Spooner, Laura L Carter

Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RORγT Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity.
Yanxia Guo, Kenzie D MacIsaac, Yi Chen, Richard J Miller, Renu Jain, Laura L Carter

Cell Rep· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.
Xiao Hu, Xikui Liu, Jacques Moisan, Yahong Wang, Charles A Lesch, Laura L Carter

Oncoimmunology· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists.
Xiao Hu, Yahong Wang, Ling-Yang Hao, Xikui Liu, Chuck A Lesch, Laura L Carter

Nat Chem Biol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists.
Xiao Hu, Yahong Wang, Ling-Yang Hao, Xikui Liu, Chuck A Lesch, Laura L Carter

Nat Chem Biol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.
Leila J Jackson, Jed A Pheneger, Tracy J Pheneger, Gregg Davis, A Dale Wright, Laura L Carter

Cell Immunol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.
Patricia W Bedard, Valerie Clerin, Natalia Sushkova, Boris Tchernychev, Thomas Antrilli, Laura L Carter

J Pharmacol Exp Ther· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
Laura L Carter, Michael W Leach, Mihai L Azoitei, Junqing Cui, Jeffrey W Pelker

J Neuroimmunol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic opportunities in the B7/CD28 family of ligands and receptors.
Beatriz M Carreno, Laura L Carter, Mary Collins

Curr Opin Pharmacol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.
Kelly-Ann Sheppard, Lori J Fitz, Julie M Lee, Christina Benander, Judith A George, Laura L Carter

FEBS Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation.
Laura L Carter, Beatriz M Carreno

Immunol Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity.
Marion T Kasaian, Matthew J Whitters, Laura L Carter, Leslie D Lowe, Jason M Jussif

Immunity· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
LauraL Carter, Lynette A Fouser, Jason Jussif, Lori Fitz, Bija Deng

Eur J Immunol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis